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Radiotherapy exerts part of its antineoplastic eﬀect by generating oxidative stress, therefore genetic variation in oxidative stress-
related enzymes may inﬂuence survival of rectal cancer patients. We hypothesized that genetic polymorphisms associated with
higher amounts of reactive oxygen species (ROS) that exaggerate cytotoxic activity could improve survival after radiotherapy. We
followed 114 rectal cancer patients who received radiotherapy for an average of 42.5 months. Associations between genotypes
(GSTP1, GSTM1, GSTT1, CAT, MnSOD, MPO and eNOS) and overall survival were assessed using Kaplan-Meier curves and Cox
proportionalhazardsregression.Ashypothesized,patientscarryinglowROSproducingeNOSGlu298Aspasparaginealleleshowed
an increased hazard of death compared to homozygous carriers of the glutamine allele (hazard ratio (HR): 2.10, 95% conﬁdence
interval (CI): 1.01–4.38). However, carriers of low ROS producing MPO G463A A allele had a decreased hazard of death compared
to patients homozygous for the G allele (HR: 0.44, 95% CI: 0.21–0.93) although patients homozygous for the A allele had a slightly
increased hazard (HR: 1.12, 95% CI: 0.25–5.08). This explorative study provides ﬁrst results and highlights the need for further,
larger studies to investigate association between genetic variation in oxidative stress genes and survival of rectal cancer patients
who received radiotherapy.
Copyright © 2009 Silvia Funke et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Radiotherapy is the current neoadjuvant and adjuvant treat-
ment standard for rectal cancer in addition to surgery [1].
In combination with chemotherapy, radiation showed eﬀec-
tiveness in tumor downstaging and has facilitated sphincter-
saving surgery in the neoadjuvant setting [2]. Radiation
exerts part of its cytotoxic eﬀects through indirect action by
producing reactive oxygen species (ROS) [3]. This oxidative
damaging potential is utilized to treat cancer by eradicating
the malignant cells through massive cellular damage to
macromolecules or indirectly through triggering abnormal
signaling and cell cycle regulation [4]. Individual variability
in enzymes participating in cell defense mechanisms against
ROS generated by radiation may account for individual
diﬀerences in prognosis.
Enzymes involved in ROS neutralizing pathways include
glutathione-S-transferases (GSTs), manganese superoxide
dismutase (MnSOD), and catalase (CAT). GSTs participate
in carcinogen metabolism and have been related to detox-
iﬁcation of products generated by UV radiation-induced
oxidative stress [5]. Furthermore, they are known to2 Journal of Cancer Epidemiology
inhibit the mitogen-activated protein (MAP) kinase path-
way through which apoptosis, stimulated by oxidative or
chemical stress, is induced. By direct binding to c-Jun-N-
terminal kinase 1 that activates the MAP kinase system, GSTs
participate in the metabolism of lipids and DNA products
derived from oxidative stress [6]. Polymorphisms in GST
genes include the GSTP1 Ile105Val polymorphism and the
deletion polymorphisms of GSTM1 or GSTT1 leading to
diminished or abolished enzyme activity [7, 8]. MnSOD
plays a crucial role in endogenous defense mechanisms
against ROS, by converting superoxide radicals to H2O2 [9].
If not subsequently removed by other antioxidant defense
enzymes, H2O2 itself can contribute to further generation
of ROS catalyzed by myeloperoxidase (MPO). The alanine
allele of MnSOD Val
9Ala polymorphism has been associated
with overexpression of MnSOD, resulting in an increased
production of H2O2, which has been proposed to generate
increased levels of ROS, if not subsequently neutralized [10].
CAT participates in defense mechanisms against oxidative
stress by controlling the intracellular concentration of H2O2
by conversion into H2Oa n dO 2 [11]. The variant T allele of
CAT C262T polymorphism has been associated with lower
enzyme activity compared to the C allele and, thus, increased
levels of ROS [12, 13].
Enzymes such as MPO and endothelial nitric oxide
synthase (eNOS) are involved in the generation of ROS.
MPO catalyzes a reaction between H2O2 and chloride to
generate hypochlorous acid, a potent oxidizing agent [14].
The G463A single nucleotide polymorphism (SNP) shows a
decreased aﬃnity of the variant A allele to the SP1 binding
site, resulting in a lower transcriptional activation. The A
allelehasthereforebeensuggestedtobeassociatedwithlower
levels of ROS [15]. eNOS generates both ROS and NO rad-
icals. NO has complex cellular eﬀects, either cytoprotective
or cytotoxic depending on its concentration [16, 17]. The
asparagine allele of eNOS Glu298Asp polymorphism has been
associated with reduced levels of NO and ROS [18].
So far, the eﬀect of genetic variants in oxidative stress
genes on survival in rectal cancer patients who received
radiation therapy has not been assessed. However, studies
in breast cancer patients have observed a survival beneﬁt for
patients with high ROS level genotypes [10, 19]. We hypoth-
esized that polymorphisms in GSTP1, GSTM1, GSTT1, CAT,
MnSOD, MPO,a n deNOS associated with high ROS levels
would prolong overall survival in rectal cancer patients who
received radiotherapy and used data of two population based
studies to evaluate this.
2.MaterialandMethods
2.1. Patient Population and Data Collection. This followup
study included 473 patients with newly diagnosed, his-
tologically proven, invasive rectal cancer recruited in a
population-based case-control study (DACHS) (n = 237)
and a population-based patient study (ESTHER II) (n =
236). Baseline inclusion criteria of the DACHS study were
residence in the Rhein-Neckar-Odenwald region, diagnosis
between January 2003 and December 2004, age of 30
years or older. Patients were eligible to participate in the
ESTHER II study if they were residents of the Saarland,
diagnosed between January 2001 and March 2003, and aged
between 50 and 74 years. Further eligibility criteria for both
studies were suﬃcient knowledge of the German language to
participate in a personal interview and availability of a blood
(DACHS/ESTHER II) or a mouthwash (DACHS) sample.
The studies were approved by the corresponding ethics
committees (Medical University of Heidelberg, State Medical
Boards of Baden-Wuerttemberg, Rhineland-Palatinate, and
Saarland, resp.). Written informed consent was obtained
from all study participants.
After an average of three years after diagnosis detailed
information on rectal cancer treatment was collected from
treating physicians. Data on vital status, date of death,
and cause of death were provided by registration oﬃces
in the Rhein-Neckar-Odenwald region and by the Saarland
Cancer Registry, respectively. Treatment information was
available for 73% (n = 346) of the patients. Patients which
provided treatment information and those without treat-
ment information did not diﬀer with respect to sex, age
distribution, stage of disease, vital status, and cause of death.
Altogether, 132 patients received radiotherapy. The
present analysis excluded patients lacking information on
vital status (n = 1), date of death (n = 1), and start of radia-
tion treatment (n = 15). In addition, patients with a survival
time below one month were excluded from analysis (n = 1).
Altogether, 114 patients (DACHS: n = 58, ESTHER II: n =
56) were eligible for analysis.
2.2. Genotyping. Genomic DNA was isolated from blood
using the FlexiGene DNA Kit (Qiagen GmbH, Hilden,
Germany) (DACHS) or from EDTA anticoagulated blood
using a previously described alcohol-precipitation based
method (ESTHER II) [20]. A 10% random sample was
genotyped twice for quality control.
GSTP1 Ile105Val polymorphism (rs1695) was analyzed
using ﬂuorescence-based melting curve analysis as described
previously [21]. Homozygous deletions of GSTM1 and
GSTT1 were assessed using a multiplex PCR followed by gel
electrophoresis as described previously [22]. SNPs in CAT
(rs1001179),MnSOD (rs4880),MPO(rs2333227),andeNOS
(rs1799983) were analyzed using polymerase chain reaction
(PCR) followed by Pyrosequencing technology (Biotage,
Uppsala, Sweden). Detailed information on primers and
cycling conditions of Pyrosequencing analyses is provided in
the supplements.
2.3. Statistical Analyses. Analysis was performed using SAS
software, version 9.1 (SAS Institute, Cary, NC, USA). All
statistical tests were two sided with a signiﬁcance level of α =
0.05. Baseline characteristics between deceased and censored
patients were compared using t-test for normally distributed
continuousvariablesandχ2-testforcategoricalvariables.For
SNPs in GSTP1, CAT, MnSOD, MPO,a n deNOS genotype
data were categorized in three categories (homozygous wild-
type allele (reference), heterozygous allele carriers, homozy-
gous variant allele carriers) as well as two categories (car-
rier status versus noncarrier). Deletion polymorphisms inJournal of Cancer Epidemiology 3
Table 1: Descriptive characteristics of deceased and censored patients.
All (N = 114) Deceased (N = 35) Censored (N = 79) P
N % N % N %
Sex .65∗
female 36 31.6 10 28.6 26 32.9
male 78 68.4 25 71.4 53 67.1
Age (years), mean 62.1 63.3 .13
†
Age groups (years) .16
∗
<49 6 5.2 4 11.4 2 2.5
50–59 19 16.7 3 8.6 16 20.3
60–69 70 61.4 21 60.0 49 62.0
70–79 18 15.8 7 20.0 11 13.9
>80 1 0.9 0 0.0 1 1.3
BMI (kg/m2), mean 26.3 26.0 1.00
†
BMI groups (kg/m2) .96
∗
<25 49 43.0 15 42.9 34 43.0
25–29.9 47 41.2 14 40.0 33 41.8
≥30 18 15.8 6 17.1 12 15.2
Stage <.01∗
1 10 8.8 1 2.9 9 11.4
2 34 29.8 5 14.3 29 36.7
3 58 50.9 19 54.3 39 49.4
4 12 10.5 10 28.5 2 2.5
∗χ2-test for diﬀerence in deceased and censored patients.
†t-test for diﬀerence in deceased and censored patients.
GSTM1 and GSTT1 were categorized as nonnull (reference)
or null genotype.
Survival time was deﬁned as time from beginning
radiation treatment to date of death or date of last contact.
Crude associations between genotypes and overall survival
were assessed using Kaplan-Meier (KM) survival function.
Testfordiﬀerencesofthesurvivorshipfunctionsbygenotype
was performed by means of log-rank test. Cox proportional
hazards regression was additionally applied to calculate
hazard ratios (HRs) and corresponding 95% conﬁdence
intervals (CI), adjusting for study, sex, and cancer stage.
Age and additional treatment with chemotherapy did not
aﬀect HRs and were therefore not included in the model.
Test for trend was performed by using the Wald statistic.
Because a small proportion of patients died from other
(n = 3) or unknown (n = 2) causes, we also conducted
Cox proportional hazards regression analyses including only
those who died from rectal cancer.
3. Results
AllSNPswereinHardy-Weinbergequilibrium.Theobserved
allele frequencies of GSTP1, CAT, MnSOD, MPO, and
eNOS were comparable to those reported for Caucasian
populations in the dbSNP database. Frequencies of GSTT1
and GSTM1 deletion polymorphisms were in accordance
with those previously reported [23].
Characteristics of the study population are presented
in Table 1.N od i ﬀerences between deceased and censored
cases were observed with respect to sex, age, and BMI.
As expected, notably more deceased patients suﬀered from
advanced rectal cancer including stage 3 and stage 4 disease
(82.8%) compared to censored patients (51.9%). Of the
114 patients who received radiotherapy, 39 individuals only
received neoadjuvant treatment, 74 patients only received
adjuvant/palliative treatment, and one patient received both
(Table 2). Altogether, 31% (n = 35) of the patients died.
Most deceased patients had stage 3 disease (54.3%).
Median followup time was 42.5 months. Plots of the
estimated KM survivorship functions did not show dif-
ferences in survival according to genotype for any of the
polymorphisms (data not shown). However, multivariate
Cox regression analyses showed a decreased hazard of death
for patients carrying MPO G463A A allele compared to
homozygous carriers of the G allele (HR: 0.44, 95% CI: 0.21–
0.93; Table 3). This ﬁnding was consistent with borderline
statistical signiﬁcance of the log-rank test comparing KM
survival curves by MPO genotype (Plog-rank:0 . 0 6 ) .P a t i e n t s
heterozygous for the MPO A allele showed a HR of 0.39
(95% CI: 0.17–0.87), whereas patients homozygous for the A
allele showed an HR of 1.12 (95% CI: 0.25–5.08) compared
to homozygous carriers of the G allele. However, only seven
patients were homozygous for MPO Aa l l e l e .
Carrying the eNOS Glu298Asp asparagine allele was
associated with a signiﬁcantly increased hazard of death
compared to homozygous carriers of the glutamine allele
(HR: 2.10, 95% CI: 1.01–4.38; Table 3). Patients carrying one
or two eNOS asparagine alleles showed an HR of 2.19 (95%4 Journal of Cancer Epidemiology
Table 2: Neoadjuvant and adjuvant/palliative radiation therapy.
Neoadjuvant (N = 40)
∗ Adjuvant/Palliative (N = 75)
∗ Deceased (N = 35)
N % N % N %
Stage 1 8 20.0 2 2.7 1 2.8
Stage 2 13 32.5 22 29.3 5 14.3
Stage 3 13 32.5 45 60.0 19 54.3
Stage 4 6 15.0 6 8.0 10 28.6
∗One patient received both neoadjuvant and adjuvant/palliative radiation therapy.
Table 3: Hazard ratios of overall mortality in rectal cancer patients who received radiation therapy according to polymorphisms in GSTP1,
GSTT1, GSTM1, CAT, MnSOD, MPO,a n d eNOS.
Genetic polymorphism N Cases/Deaths Person-years Death/Person-years Plog-rank HR
§ (95% CI) Ptrend
GSTP1
Ile/Ile 54/16 194.5 0.08 1
Ile/Val 51/17 174.3 0.10 1.18 (0.58–2.40)
Val/Val 9/2 33.0 0.06 .75 0.85 (0.19–3.85) .88
Val carriers 1.14 (0.57–2.28)
GSTM1
nonnull 61/16 218.0 0.07 1
null 53/19 183.8 0.10 .35 1.64 (0.84–3.21) .15
GSTT1
nonnull 91/31 321.5 0.10 1
null 23/4 80.3 0.05 .17 0.68 (0.23–2.00) .49
CAT
C/C 65/20 225.2 0.09 1
C/T 43/13 156.4 0.08 1.37 (0.65–2.87)
T/T 6/2 20.1 0.10 .96 0.58 (0.13–2.71) .98
T carriers 1.16 (0.58–2.30)
MnSOD
Val/Val 25/8 96.6 0.08 1
Val/Ala 67/20 230.7 0.09 0.76 (0.31–1.85)
Ala/Ala 20/7 68.5 0.10 .93 0.83 (0.27–2.51) .75
Ala carriers 0.78 (0.33–1.84)
MPO
G/G 64/25 207.2 0.12 1
G/A 43/8 172.2 0.05 0.39 (0.17–0.87)
A/A 7/2 22.5 0.09 .06 1.12 (0.25–5.08) .09
A carriers 0.44 (0.21–0.93)
eNOS
Glu/Glu 51/12 194.7 0.06 1
Glu/Asp 53/20 175.5 0.11 2.19 (1.04–4.61)
Asp/Asp 10/3 31.7 0.09 .29 1.56 (0.41–6.01) .12
Asp carriers 2.10 (1.01–4.38)
§Cox proportional hazards model adjusted for sex, study, and cancer stage.
CI: 1.04–4.61) and 1.56 (95% CI: 0.41–6.01), respectively, as
compared to patients homozygous for the glutamine allele.
None of the other polymorphisms under study were
found to be signiﬁcantly associated with survival in rectal
cancer patients who received radiotherapy. Associations
between polymorphisms and rectal cancer-speciﬁc survival
were similar to those investigating overall survival (data not
shown).
4. Discussion
This study is the ﬁrst explorative analysis to evaluate the
eﬀect of genetic polymorphisms in genes related to oxidative
stress mechanisms on survival of rectal cancer patients after
radiotherapy. Our data provide ﬁrst suggestive evidence
of an association between genetic variants and survival in
rectal cancer patients who received ROS producing radiationJournal of Cancer Epidemiology 5
therapy. Due to genetic variation, higher amounts of ROS
reaching tumor cells and exaggerating cytotoxic activity
may increase survival. Since radiotherapy exerts part of its
antineoplastic eﬀect via the generation of oxidative stress,
we assessed whether genotypes related to high levels of ROS
may prolong survival in patients who received radiotherapy.
As hypothesized, patients carrying eNOS Glu298Asp low
ROS producing asparagine allele showed increased hazard of
deathascomparedtononcarriers.Thisﬁndingisbiologically
plausible as the eNOS asparagine allele has been related to
low ROS levels [18]. Our ﬁnding is in line with a study in
873 breast cancer patients that observed a shorter survival in
patients carrying the eNOS asparagine allele [19]. However,
that study did not provide information on type of treatment
that the patients received. Treatment and clinical course
of rectal cancer and breast cancer are completely diﬀerent;
therefore comparison of results may not be useful.
Carrying low ROS producing MPO G463A A allele
was associated with reduced hazard of death compared
to noncarriers, but there was no allele dose eﬀect. This
observation lacks biological plausibility as the MPO Ga l l e l e
has been suggested to be associated with high levels of
R O S ,a n dg e n o t y p e sr e l a t e dt oh i g hl e v e l so fo x i d a t i v e
stress have been proposed to prolong survival [10, 15]. A
study of breast cancer patients indeed observed a survival
beneﬁt for patients homozygous for the MPO Ga l l e l ew h o
received treatment with chemo- and/or radiotherapy [10].
Nonetheless, our study showed a nonsigniﬁcantly increased
H Rf o rp a t i e n t sh o m o z y g o u sf o rt h eAa l l e l eb a s e do nas m a l l
number of patients.
Since our study is limited in size and a large number of
associations were tested, chance ﬁndings with regard to the
eﬀect of eNOS and MPO polymorphisms on survival cannot
b er u l e do u t .H o w e v e r ,r e c a l lb i a sc o u l dn o th a v eo c c u r r e d
in this study as we collected information about treatment
modalities from the treating physicians. Nevertheless, it
cannot be excluded that the treatment data were more likely
provided on patients who were still alive or recently deceased
causing selection bias.
Despite biological evidence that radiation exerts part of
its eﬀect via the generation of oxidative stress, the eﬀect of
genetically determined diﬀerences in oxidative stress mecha-
nisms on survival after radiotherapy is not well understood.
Further, larger studies providing detailed information about
duration and intensity of radiation treatment are required to
clarify the association of eNOS Glu298Asp and MPO G463A
polymorphisms with survival in rectal cancer patients who
received radiotherapy. Altogether, our ﬁndings highlight the
need for further research on putative genetic markers in
rectal cancer patients treated with radiotherapy.
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